OssDsign Past Earnings Performance
Past criteria checks 0/6
OssDsign has been growing earnings at an average annual rate of 11.5%, while the Medical Equipment industry saw earnings growing at 21.1% annually. Revenues have been growing at an average rate of 37.3% per year.
Key information
11.46%
Earnings growth rate
37.53%
EPS growth rate
| Medical Equipment Industry Growth | 6.16% |
| Revenue growth rate | 37.34% |
| Return on equity | -16.02% |
| Net Margin | -27.75% |
| Next Earnings Update | 18 Aug 2026 |
Recent past performance updates
Recent updates
Narrative Update • Jul 17
nan
Analysts have reduced their price target for OssDsign from SEK 17.50 to SEK 9.00, citing updated assumptions for revenue growth, profit margins, and a lower future P/E multiple. What’s in the News for OssDsign No recent OssDsign specific news items were identified in the provided sources.
Narrative Update • Jul 02
OSSD: Higher Margin Outlook And Lower P/E Will Support Future Re Rating
Analysts have adjusted their price target on OssDsign to SEK 6.40 from SEK 12.75, citing updated assumptions around revenue growth, profit margins, and a lower future P/E multiple. What’s in the News for OssDsign OssDsign issued earnings guidance for the first quarter of 2026, indicating an expected loss before interest and taxes in the range of SEK 12.0 million to SEK 14.0 million, according to company guidance.
Narrative Update • Jun 18
OSSD: Refined Forecast Assumptions And Q1 2026 Guidance Support Upside Potential
Analysts have kept their OssDsign price target steady at SEK5.10, with only small tweaks to inputs such as discount rate, revenue growth, profit margin and future P/E, which feed into an unchanged fair value view. What’s in the News for OssDsign OssDsign issued earnings guidance for the first quarter of 2026, indicating an expected loss before interest and taxes in a range of SEK 12.0 million to SEK 14.0 million.Narrative Update • Jun 04
OSSD: Refined Forecast Assumptions Will Support Future Upside Potential
Analysts have maintained their SEK fair value estimate for OssDsign while updating inputs such as revenue growth, profit margin, discount rate and a lower future P/E assumption. Together, these changes support a refined price target framework without altering the headline SEK figure.Narrative Update • May 03
OSSD: Higher Long Term Margins And Moderate P/E Will Support Future Upside
Analysts have revised their price target for OssDsign to SEK 5.1 from SEK 13.5. The change reflects updated assumptions around growth, profitability and a more moderate future P/E multiple. What's in the News OssDsign issued earnings guidance for the first quarter of 2026, indicating a loss before interest and taxes in the range of SEK 12.0 million to SEK 14.0 million, with only marginal exchange rate impact (Key Developments).Narrative Update • Apr 18
OSSD: Stable Loss Outlook And Assumptions Will Support Future Multiple Re Rating
Analysts have kept their OssDsign price target steady at SEK 12.75, indicating only marginal tweaks in the discount rate, long term revenue growth, profit margin and future P/E assumptions, rather than any major shift in their view of the company. What's in the News OssDsign issued earnings guidance for the first quarter of 2026, focusing on loss before interest and taxes rather than revenue or profit metrics.Narrative Update • Apr 04
OSSD: Stable Profitability Assumptions Will Support Future Multiple Re rating
Analysts keep their SEK 12.75 price target on OssDsign unchanged, citing steady assumptions around growth, margins, and a future P/E near 113x as the basis for maintaining the current valuation. Valuation Changes Fair Value: SEK 12.75 remains unchanged, so the target valuation level is consistent with prior assumptions.Narrative Update • Mar 20
OSSD: Stable Assumptions Will Support Long Term Margin Expansion
Analysts have maintained their SEK 12.75 price target for OssDsign, citing stable assumptions on fair value, discount rate, revenue growth, profit margin and future P/E as the basis for this unchanged view. Valuation Changes Fair Value: SEK 12.75 remains unchanged, signalling a stable central valuation estimate.Narrative Update • Mar 05
OSSD: New US Leadership Will Support Long Term Margin Expansion
Analysts have kept their OssDsign price target steady at SEK 12.75, citing largely unchanged assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E as the basis for maintaining their view. What's in the News OssDsign AB appointed Mark Waugh as CEO, effective January 1, 2026, following his senior roles at Smith & Nephew plc, Medtronic Sofamor Danek Inc, and Medacta USA (Key Developments).Narrative Update • Feb 19
OSSD: New US-Focused Leadership Will Support Long Term Margin Expansion
Analysts are maintaining their SEK 12.75 price target on OssDsign. They point to a slightly higher discount rate, broadly similar revenue growth assumptions at around 26%, a lower profit margin outlook, and a higher future P/E expectation as key inputs behind this unchanged view.Narrative Update • Feb 04
OSSD: US Leadership Change Will Support Long Term Margin Expansion
Analysts have reduced their price target on OssDsign to €12.75 from €15.50, citing updated assumptions for growth, margins, and a lower future P/E multiple. What's in the News OssDsign AB appointed Mark Waugh as CEO, with his tenure set to begin on January 1, 2026, following a leadership transition from current CEO Morten Henneveld (Key Developments).Narrative Update • Jan 20
OSSD: New US Based Leadership Will Drive Future Orthobiologics Expansion
Analysts have kept their price target for OssDsign steady at €13.50, citing only marginal adjustments to the discount rate, revenue growth, profit margin and forward P/E assumptions that together are not enough to shift their overall valuation view. What's in the News OssDsign AB appointed Mark Waugh as CEO, effective January 1, 2026, following his senior roles at Smith & Nephew, Medtronic Sofamor Danek, and Medacta USA (company announcement).Narrative Update • Jan 06
OSSD: New US Focused Leadership Will Shape Bullish Future Outlook
Analysts have adjusted their price target on OssDsign to $13.50, reflecting updated assumptions around revenue growth, profit margin and a much higher implied future P/E multiple, while keeping their fair value estimate unchanged at $13.50. What's in the News OssDsign AB appointed Mark Waugh as CEO, effective January 1, 2026, following five years of leadership under outgoing CEO Morten Henneveld (Key Developments).Narrative Update • Dec 13
OSSD: New Leadership And Index Inclusion Will Shape Balanced Future Outlook
The analyst price target for OssDsign has been raised from SEK 12.0 to SEK 13.5, as analysts factor in a higher long term valuation multiple despite slightly slower projected revenue growth and a softer profit margin profile. What's in the News OssDsign AB appointed Mark Waugh as CEO, effective January 1, 2026, succeeding Morten Henneveld after five years of leading the company through growth and transformation (company announcement) New CEO Mark Waugh brings over 20 years of international leadership experience across major orthopedic segments in the USA and Europe, including senior roles at Smith & Nephew, Medtronic Sofamor Danek, and Medacta USA (company announcement) OssDsign Catalyst driven orthobiologics focus has supported strong double digit growth in the U.S. market since its launch in August 2021 (company announcement) OssDsign AB (publ) has been added to the S&P Global BMI Index, increasing its visibility to international institutional investors (index provider) Valuation Changes Fair Value: Raised from SEK 12.0 to SEK 13.5, reflecting a modest upward revision in the company’s long term valuation.Narrative Update • Aug 08
Pure Play Orthobiologics Will Expand US Healthcare Access
With OssDsign's consensus price target revised lower, primarily driven by a notable drop in its Future P/E from 77.22x to 64.47x, the fair value estimate has decreased from SEK15.67 to SEK14.83. What's in the News An undisclosed buyer acquired an unknown minority stake in OssDsign AB from Karolinska Development AB.Analysis Article • May 08
Optimistic Investors Push OssDsign AB (publ) (STO:OSSD) Shares Up 31% But Growth Is Lacking
OssDsign AB (publ) ( STO:OSSD ) shareholders would be excited to see that the share price has had a great month...
New Narrative • Apr 07
Pure Play Orthobiologics Will Expand US Healthcare Access
Strategic shift to orthobiologics boosts growth and operational efficiency, enhancing future revenue and sustaining high net margins.Analysis Article • Feb 21
OssDsign AB (publ)'s (STO:OSSD) 25% Price Boost Is Out Of Tune With Revenues
OssDsign AB (publ) ( STO:OSSD ) shares have continued their recent momentum with a 25% gain in the last month alone...Analysis Article • Feb 07
Analysts Are Upgrading OssDsign AB (publ) (STO:OSSD) After Its Latest Results
OssDsign AB (publ) ( STO:OSSD ) defied analyst predictions to release its full-year results, which were ahead of market...Analysis Article • Nov 15
OssDsign AB (publ) (STO:OSSD) Just Reported Earnings, And Analysts Cut Their Target Price
OssDsign AB (publ) ( STO:OSSD ) just released its latest quarterly results and things are looking bullish. OssDsign...Analysis Article • Nov 13
OssDsign AB (publ)'s (STO:OSSD) Share Price Matching Investor Opinion
OssDsign AB (publ)'s ( STO:OSSD ) price-to-sales (or "P/S") ratio of 5.7x might make it look like a sell right now...Analysis Article • Aug 23
OssDsign AB (publ) (STO:OSSD) Just Reported Earnings, And Analysts Cut Their Target Price
Last week, you might have seen that OssDsign AB (publ) ( STO:OSSD ) released its quarterly result to the market. The...Analysis Article • Aug 06
We Think OssDsign (STO:OSSD) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analysis Article • Jun 19
Increases to OssDsign AB (publ)'s (STO:OSSD) CEO Compensation Might Cool off for now
Key Insights OssDsign's Annual General Meeting to take place on 25th of June CEO Morten Henneveld's total compensation...Analysis Article • Mar 19
Getting In Cheap On OssDsign AB (publ) (STO:OSSD) Is Unlikely
OssDsign AB (publ)'s ( STO:OSSD ) price-to-sales (or "P/S") ratio of 8.5x might make it look like a strong sell right...Revenue & Expenses Breakdown
Revenue & Expenses Breakdown
How OssDsign makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 26 | 173 | -48 | 195 | 18 |
| 31 Dec 25 | 180 | -51 | 202 | 20 |
| 30 Sep 25 | 176 | -42 | 184 | 22 |
| 30 Jun 25 | 168 | -46 | 179 | 23 |
| 31 Mar 25 | 151 | -53 | 169 | 23 |
| 31 Dec 24 | 134 | -50 | 152 | 23 |
| 30 Sep 24 | 127 | -90 | 151 | 25 |
| 30 Jun 24 | 123 | -114 | 149 | 26 |
| 31 Mar 24 | 118 | -118 | 145 | 27 |
| 31 Dec 23 | 112 | -130 | 143 | 29 |
| 30 Sep 23 | 97 | -109 | 131 | 29 |
| 30 Jun 23 | 83 | -95 | 113 | 40 |
| 31 Mar 23 | 71 | -99 | 142 | 8 |
| 31 Dec 22 | 57 | -99 | 113 | 25 |
| 30 Sep 22 | 46 | -96 | 111 | 17 |
| 30 Jun 22 | 38 | -93 | 115 | 0 |
| 31 Mar 22 | 33 | -95 | 107 | 0 |
| 31 Dec 21 | 32 | -94 | 104 | 0 |
| 30 Sep 21 | 29 | -90 | 100 | 0 |
| 30 Jun 21 | 27 | -92 | 100 | 0 |
| 31 Mar 21 | 23 | -90 | 94 | 0 |
| 31 Dec 20 | 25 | -85 | 92 | 0 |
| 30 Sep 20 | 24 | -89 | 96 | 0 |
| 30 Jun 20 | 22 | -89 | 97 | 0 |
| 31 Mar 20 | 22 | -85 | 94 | 0 |
| 31 Dec 19 | 18 | -84 | 90 | 0 |
| 30 Sep 19 | 18 | -72 | 80 | 0 |
| 30 Jun 19 | 20 | -66 | 73 | 0 |
| 31 Mar 19 | 21 | -62 | 68 | 0 |
| 31 Dec 18 | 21 | -56 | 63 | 0 |
| 31 Dec 17 | 16 | -63 | 52 | 0 |
Quality Earnings: OSSD is currently unprofitable.
Growing Profit Margin: OSSD is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OSSD is unprofitable, but has reduced losses over the past 5 years at a rate of 11.5% per year.
Accelerating Growth: Unable to compare OSSD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OSSD is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (5.2%).
Return on Equity
High ROE: OSSD has a negative Return on Equity (-16.02%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/17 13:43 |
| End of Day Share Price | 2026/08/14 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
OssDsign AB (publ) is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| null null | ABG Sundal Collier Sponsored |
| Kristofer Liljeberg-Svensson | DNB Carnegie Commissioned Research |